Theranos fallout still curbs diagnostics funding and public trust after a decade
Scientists say Theranos’s collapse and Elizabeth Holmes’s fraud still shape biotech funding and trust a decade later. Private investors now avoid diagnostics startups, shrinking grants and slowing patient-ready blood tests across academic labs. Researchers warn secrecy and marketing pressure let faulty technologies reach the public and harm patients who need reliable tests.
Where this came from. One outlet reported this. We read it, then wrote the sixty words above.